Skip to main content

Table 1 Patient characteristics at baseline

From: The relationship of weight change trajectory with medial temporal lobe atrophy in patients with mild Alzheimer’s disease: results from a cohort study

Age (year): n, median [25th -75th percentile] 214, 79 [75 - 82]
Women, n (%) 132 (61.7)
Social status  
 alone, n (%) 93 (44.9)
 with partner, n (%) 108 (52.2)
 other*, n (%) 6 (2.9)
CIRS (score): n, median [25th -75th percentile] 214, 6.0 [4.0- 8.0]
Number of medications beside ChEI  
 ≤4, n (%) 100 (46.9)
 >4 (polypharmacy), n (%) 113 (53.1)
Use of informal care, n (%) 182 (85.4)
Use of professional care, n (%) 99 (46.9)
MMSE (score): n, median [25th -75th percentile] 212, 23 [20 - 25]
 MMSE score ≤24, n (%) 138 (65.1)
 MMSE >26, n (%) 33 (15.6)
 Mild AD (MMSE 21 - 26), n (%) 126 (59.4)
 Moderate AD (MMSE 10 - 20), n (%) 53 (25.0)
 Moderate severe AD (MMSE 10 - 14), n (%) 3 (1.4)
 Severe AD (MMSE <10), n (%) 0 (0)
Clock-drawing test (score): n, median [25th -75th percentile] 193, 3.0 [2.0 - 4.5]
 Clock-drawing test score ≥3, n (%) 140 (72.5)
Presence of BPS, n (%) 51 (24.4)
ChEI which was started  
 galantamine, n (%) 209 (97.7)
 rivastigmine, n (%) 5 (2.3)
Weight (kg): n, mean ± SD 214, 73.8 ± 12.0
BMI (weight/(height)2): n, median [25th -75th percentile] 203, 25.8 [23.5 - 28.6]
Use of ONS, n (%) 1 (0.5)
Appetite  
 good, n (%) 170 (92.9)
 poor, n (%) 13 (7.1)
Self-reported weight loss, n (%) 28 (14.4)
Left MTA score  
 0 (no atrophy), n (%) 1 (0.5)
 1 (mild atrophy), n (%) 15 (7.0)
 2 (moderate atrophy), n (%) 111 (51.9)
 3 (severe atrophy), n (%) 65 (30.4)
 4 (very severe atrophy), n (%) 22 (10.3)
Right MTA score  
 0 (no atrophy), n (%) 2 (0.9)
 1 (mild atrophy), n (%) 15 (7.0)
 2 (moderate atrophy), n (%) 108 (50.5)
 3 (severe atrophy), n (%) 74 (34.6)
 4 (very severe atrophy), n (%) 15 (7.0)
  1. *Other, that is: with son or daughter, brother or sister. n, number of patients; CIRS, cumulative illness rating scale; ChEI, cholinesterase inhibitor; MMSE, mini mental state examination; AD, Alzheimer’s disease; BPS, behavioral and psychological symptoms; SD, standard deviation; BMI, body mass index; ONS, oral nutritional supplement; MTA, medial temporal lobe atrophy.